Trial Profile
Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women With Hormone Receptor-Positive Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 01 Feb 2022 Results from TARGET study and four (CALGB/Alliance) clinical trials identifying predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach published in the Pharmacogenomics Journal
- 06 Oct 2021 Results of a meta-analysis of a for clinical studies assessing genome-wide association with either hypertension or proteinuria across the different studies (NCT00785291, NCT00601900, NCT00088894 and NCT00110214) published in the British Journal of Cancer
- 25 Jun 2020 Results published in the Clinical Cancer Research